BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114

Core Insights - The study published in Cell Reports provides mechanistic evidence for the role of β2-spectrin in obesity-related liver diseases, suggesting that targeting this protein with BF-114 can prevent disease progression [1][2] - BF-114 has shown potential in treating metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC) [1][2] - Dr. Lopa Mishra has joined BullFrog AI's Scientific Advisory Board to provide strategic insights for advancing BF-114 [1][5] Research Findings - The research indicates that β2-spectrin mediates the effects of environmental factors driving MASH progression, and BF-114 can reduce β2-spectrin levels to halt MASLD and MASH progression in animal models [2][3] - Previous studies from Dr. Mishra's laboratory support the development of BF-114 for obesity and liver diseases [3] Development Strategy - BullFrog AI plans to utilize its AI-driven platform to analyze single-cell data from animal models and human patients, which will enhance understanding of SPTBN1 silencing effects in obesity and liver disease [4] - Insights from this analysis are expected to inform the continued development of BF-114 and may uncover additional therapeutic applications [4] Leadership and Expertise - Dr. Lopa Mishra brings extensive expertise to BullFrog AI, with over 100 peer-reviewed publications and an H-Index of 66, which will be instrumental in guiding the BF-114 program [5][6] - The company emphasizes the combination of its drug development approach and promising results from BF-114 as a strong foundation for exploring its potential in treating obesity and liver diseases [6] Company Overview - BullFrog AI is a technology-enabled drug development company leveraging artificial intelligence and machine learning for pharmaceutical and biologic development [7] - The company's proprietary bfLEAP™ platform is being utilized for the development of BF-114 targeting obesity and liver diseases [7]